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Cerebrovascular dysfunction significantly contributes to the clinical presentation and pathoetiology of
Alzheimer’s disease (AD). Deposition and aggregation of b-amyloid (Ab) within vascular smooth muscle cells
leads to inflammation, oxidative stress, impaired vasorelaxation, and disruption of blood-brain barrier integ-
rity. Midlife vascular risk factors, such as hypertension, cardiovascular disease, diabetes, and dyslipidemia,
increase the relative risk for AD. These comorbidities are all characterized by low and/or dysfunctional high-
density lipoproteins (HDL), which itself is a risk factor for AD. HDL performs a wide variety of critical functions
in the periphery and CNS. In addition to lipid transport, HDL regulates vascular health via mediating vasore-
laxation, inflammation, and oxidative stress and promotes endothelial cell survival and integrity. Here, we
summarize clinical and preclinical data examining the involvement of HDL, originating from the circulation
and from within the CNS, on AD and hypothesize potential synergistic actions between the two lipoprotein
pools.Introduction
Alzheimer’s disease (AD) is the leading cause of senile dementia
and represents a rapidly growing burden to the healthcare sys-
tem (Mayeux and Stern, 2012). In the last decade, it has become
apparent that in addition to the amyloid plaques and neurofibril-
lary tangles (NFTs) that define AD, most AD patients also have
biochemical, morphological, and functional changes to the cer-
ebrovasculature, suggesting that cerebrovascular damage is
an important aspect of AD pathophysiology (de la Torre, 1999;
Zlokovic, 2011). Many elderly patients with AD also present
with a variety of comorbid conditions, such as cardiovascular
disease (CVD), type 2 diabetes mellitus (T2DM), hypertension,
hypercholesterolemia, obesity, and stroke, all of which have
been implicated as risk factors for AD (Duron and Hanon,
2008; Faraco and Iadecola, 2013; Mayeux and Stern, 2012; She-
pardson et al., 2011a; Vagelatos and Eslick, 2013). As cerebro-
vascular changes can be detected prior to cognitive decline,
interest in how cerebrovascular function may contribute to AD
pathogenesis is rapidly increasing. Several excellent reviews
on this subject have appeared in the past three years that
discuss, among many other topics, the central importance of
the neurovascular unit and blood-brain barrier (BBB) in cerebro-
vascular function (de la Torre, 2012; Zlokovic, 2011) and new
perspectives from neuroimaging (Johnson et al., 2012). In this
article, we focus particular attention on how apolipoprotein E
(apoE)- and apolipoprotein A-I (apoA-I)-containing lipoproteins
may work synergistically to optimize cerebrovascular health.
ApoE is the major apolipoprotein produced within the brain
and forms lipoprotein particles that resemble high-density lipo-
proteins (HDLs) found in plasma (Fagan et al., 1999; Pitas
et al., 1987). ApoE has a verified genetic association with AD
risk and has both b-amyloid (Ab)-dependent and Ab-independ-
ent functions that impact cerebrovascular function (Zlokovic,
2013). ApoA-I is produced in the liver and intestine and is the574 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.major protein component of plasma HDL (Brunham et al.,
2006). Several observations raise considerable interest in the
potential protective role of plasma HDL and apoA-I on cerebro-
vascular health. For example, HDL has a well-established role
in promoting endothelial health, several comorbidities associ-
ated with increased AD risk are themselves associated with
decreased HDL function (Riwanto and Landmesser, 2013),
apoA-I is found in cerebrospinal fluid (CSF) (Koch et al., 2001),
and genetic manipulation of apoA-I levels selectively affects
vascular amyloid load in animal model studies (Lefterov et al.,
2010; Lewis et al., 2010). Here, we provide a critical review of
clinical and preclinical evidence regarding the involvement of
apoE- and apoA-I- containingHDL on vascular health to facilitate
an integrated view of whole-body lipoprotein physiology on the
pathogenesis of AD in context with its common comorbidities.
We then develop a model wherein the synergistic actions of
apoA-I- and apoE-containing lipoproteins regulate optimal cere-
brovascular health.
Clinical and Pathological Evidence of Altered
Cerebrovascular Function in AD
Impaired Cerebral Blood Flow and Glucose Metabolism
Are Early Clinical Features of AD
The brain is a markedly vascularized organ with a very high
energy demand, using 20% of the body’s cardiac output, 20%
of oxygen consumption, and 25% of glucose consumption. As
such, even minor perturbations in cerebral blood flow (CBF)
can profoundly affect neuronal health (de la Torre, 2012; Zlo-
kovic, 2008). In AD patients, CBF is reduced by 10%–30% in
the tempoparietal, frontal, and posterior cingulate cortex and
hippocampus, and the extent of CBF impairment correlates
with disease severity (Hanyu et al., 2010; Jagust et al., 1997;
Johnson et al., 1998; Kim et al., 2013a). Reduced CBF and/or
CBF dysregulation is detectable prior to cognitive decline, brain
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(Bookheimer et al., 2000; Lind et al., 2006; Ruitenberg et al.,
2005; Sheline et al., 2010; Smith et al., 1999; Wierenga et al.,
2013; Wishart et al., 2006). Dysregulated CBF is also observed
in several AD mouse models prior to plaque development (Nico-
lakakis and Hamel, 2011). Furthermore, glucose uptake and uti-
lization, as measured by FDG-PET, is decreased in AD and mild
cognitive impairment (MCI) patients (Herholz, 2010; Jagust et al.,
2010; Shin et al., 2010) as well as in transgenic animal models of
AD (Nicolakakis and Hamel, 2011). These observations raise
important questions as to whether vascular dysfunction contrib-
utes causally to AD rather than being a result of amyloid and NFT
formation. As vascular changes can be documented prior to the
onset of cognitive impairment or amyloid accumulation, a two-hit
vascular hypothesis has been proposed by Zlokovic et al. stating
that initial insults to the vascular system lead to BBB dysfunction
and oligaemia, leading to a cascade of detrimental events that
culminate in AD (Zlokovic, 2011). Progressive neuropathological
changes may drive further cerebrovascular dysfunction, result-
ing in the marked damage to the cerebrovasculature that is
observed post mortem.
Morphological and Functional Damage to the
Cerebrovasculature in AD
Brain tissue from AD patients often shows greatly reduced
microvascular density, with many of the remaining vessels
appearing tortuous, twisted, or string-like. Increased deposition
of extracellular matrix proteins, including collagen, heparin sul-
fate proteoglycan, and laminin, thickens the basement mem-
branes of cerebrovascular endothelial cells, which themselves
are lost as AD progresses. In addition to these morphological
changes, the contractile ability of the vessel is impaired due to
substantial atrophy of vascular smooth muscle cells (VSMCs)
in arteries and arterioles and reduced pericyte density in small
capillaries (Iadecola, 2004; Zlokovic, 2005). These changes are
observed in both AD subjects as well as multiple preclinical
mousemodels of AD (Lee et al., 2012). The subsequent stiffening
of the cerebral vessel results in a decreased ability to meet the
brain’s demand for oxygen and key nutrients as well as remove
neurotoxic substances.
Endothelial cells in the (CNS) form the core of the BBB. These
cells are joined by specialized tight and adherens junction pro-
teins, allowing them to form a highly selective and sensitive bar-
rier that regulates the transport of nutrients into and egress of
waste products out of the brain (Zlokovic, 2011). In AD, endothe-
lial expression of tight junction proteins and their adaptor mole-
cules is decreased, potentially due to increased expression of
matrix metalloproteases (MMPs) (Rosenberg, 2009). Subse-
quently, BBB integrity is compromised (Farrall and Wardlaw,
2009), resulting in increased bulk fluid flow and CNS access of
potentially damaging serum proteins such as immunoglobulin
G (IgG), albumin, thrombin, plasmin, and fibrin (Zlokovic, 2011).
Microvessels extracted from AD brain tissue appear to be irre-
versibly activated, expressing increased levels of nitric oxide
(NO); cytokines such as tumor necrosis factor alpha (TNF-a),
transforming growth factor b1 (TGF-b1), interleukin-1b (IL-1b),
and IL-6; chemokines such as monocyte chemoattractant pro-
tein 1 (MCP1) and IL-8; prostaglandins; MMPs; and leukocyte
adhesion molecules including intracellular adhesion molecule 1
(ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), andE-selectin (Grammas, 2011). This activation leads to aberrant
angiogenesis, increased inflammation, and oxidative stress.
Formation and Clearance of Ab
AD is defined by the presence of amyloid plaques composed
mainly of aggregated Ab peptides and NFTs that are composed
of abnormally hyperphosphorylated tau protein. Sequential
cleavage of amyloid precursor protein (APP) by b-secretase
and g-secretase produces Ab peptides that range from 36–
43 aa in length. The most relevant Ab isoforms for AD patho-
genesis are Ab42, which is very fibrillogenic and the major
component of parenchymal amyloid plaques, and Ab40, which
is the major Ab species found in cerebrovascular amyloid de-
posits (Masters and Selkoe, 2012).
In addition to parenchymal amyloid plaques, approximately
80% of AD patients exhibit Ab accumulation in the walls of
capillaries, arterioles, and small- and medium-sized arteries of
the cerebral cortex and leptomeninges, which is known as cere-
bral amyloid angiopathy (CAA) (Attems et al., 2011). Ab deposits
within the tunica media eventually lead to atrophy and acellular
replacement of the VSMC layer, which impairs vasomotor func-
tion and weakens the vessel wall.
Progressive impairments in the clearance of Ab peptides due
to aging and genetic determinants are believed to be a leading
cause of Ab accumulation in brain tissue and the cerebrovascu-
lature for the majority of AD subjects. Ab is catabolized by three
major pathways, two of which involve the cerebrovasculature
(Zlokovic, 2013). First, within the brain, Ab is enzymatically
degraded by several peptidases, most importantly by neprilysin
and insulin-degrading enzyme (IDE). Neprilysin and IDE expres-
sion is decreased in AD, and the observations that enhanced
expression of these enzymes reduces Ab burden and improves
cognitive function in murine models of AD raise interest in their
therapeutic potential (Saido and Leissring, 2012). Second, Ab
is cleared via bulk flow along perivascular drainage pathways
into the CSF and cervical lymph nodes (Weller et al., 2008). Peri-
vascular drainage of several interstitial fluid (ISF) solutes,
including Ab, from the brain is hypothesized to be driven by pul-
sations of cerebrovascular walls. As both CAA and age stiffen the
vessel and impede vessel contraction, transit of Ab along peri-
vascular drainage pathways is prolonged (Schley et al., 2006).
Finally, Ab is transported across the BBB via the low-density
lipoprotein (LDL) receptor-related protein 1 (LRP1) into the
bloodstream for eventual degradation in the liver. In both human
AD subjects and murine AD models, BBB expression of LRP1 is
decreased, while expression of the receptor of advanced glyca-
tion endproducts (RAGE), which is responsible for influx of Ab
into the brain, is increased, potentially disrupting Ab homeosta-
sis (Sagare et al., 2012). Interestingly, sterol regulatory element-
binding protein-2 (SREPB-2), a master regulator of cholesterol
homeostasis, is the only known transcriptional suppressor of
LRP1 (Llorente-Corte´s et al., 2006). Bell et al. recently reported
that the transactivation of SREBP-2 in AD VSMC resulted in
decreased LRP expression and subsequently impaired Ab clear-
ance (Bell et al., 2009). Consistent with these observations, APP/
PS1 mice that overexpress SREPB-2 exhibit increased Ab accu-
mulation (Barbero-Camps et al., 2013). In addition to SREBP-2,
the scavenger receptor CD36, which is implicated (among other
functions) in lipid transport, enhances Ab deposition and CAA
in vivo. Indeed, mice lacking CD36 have significantly reducedCell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc. 575
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fluence of lipid metabolism on Ab accumulation within the brain
vasculature.
Effect of Cerebrovascular Amyloid on BBB Integrity and
Vascular Tone
Accumulation of Ab within and around cerebral blood vessels
very likely contributes to neurovascular damage in AD (Attems
et al., 2011). Although endothelial cells appear to remain rela-
tively untouched by CAA, in vitro experiments show that addition
of vasculotrophic Ab40 peptides to confluent monolayers of
human brain endothelial cells derived either from healthy
controls or AD cases increases inflammation and enhances
attachment and transendothelial migration of peripheral blood
monocytes (Fiala et al., 1998; Giri et al., 2000, 2002) Exposure
of human or rodent cultured endothelial cells to Ab40 also leads
to decreased levels of several tight junction and adherens pro-
teins, including claudin-1 and claudin-5, occludin, and ZO-1
(Gonzalez-Velasquez et al., 2008; Hartz et al., 2012; Marco and
Skaper, 2006; Tai et al., 2010), and microvessels isolated from
CAA cases also show a significant loss of occludin, claudin-5,
and ZO-1 (Carrano et al., 2011). Ab may also impact vascular
tone by altering the reaction to vasoconstrictors and vasodila-
tors. In vivo, APP overexpression significantly and selectively
impairs endothelium-dependent cortical microcirculation (Iade-
cola et al., 1999), which is highly correlated to brain Ab concen-
tration and replicated by topical neocortical superfusion of Ab40,
but not Ab42, in wild-typemice (Niwa et al., 2000b). Ex vivo, Ab40
causes endothelium-dependent vasoconstriction in normal
blood vessels (Thomas et al., 1996; Townsend et al., 2002),
and intrathecal injection of Ab40 into wild-type and APP trans-
genic mice impairs the responses to several endothelium-
dependent vasodilators (Niwa et al., 2000a). Taken together,
both in vitro and in vivo results suggest that Ab impairs BBB
integrity and alters vascular tone.
Comorbid Conditions Associated with Increased AD
Risk Affect Cerebrovascular Function
If cerebrovascular deficits contribute to the pathogenesis of AD,
then it is reasonable to hypothesize that conditions that affect
vascular health would increase AD risk. Aging, which is one of
the strongest environment risk factors for AD (Mayeux and Stern,
2012), decreases microvascular density and increases the num-
ber of tortuous and string vessels in the CNS, which results in
reduced CBF. Aging is also associated with increased collagen
deposition in basement membranes, which thickens and stiffens
the vessel (Brown et al., 2011). In addition to normal aging, a large
body of epidemiological evidence suggests that several midlife
vascular risk factors (VRFs), such as hypertension (Faraco and
Iadecola, 2013), T2DM (Vagelatos and Eslick, 2013), CVD, and
dyslipidemia (Shepardson et al., 2011a), may also contribute to
an increased risk for vascular dementia and AD later in life (Duron
and Hanon, 2008; Mayeux and Stern, 2012). Importantly, the
presence of VRF can exacerbate the clinical presentation and in-
crease the rate of cognitive decline inMCI and ADpatients (Gold-
stein et al., 2013; Helzner et al., 2009; Mielke et al., 2007, 2011).
Hypertension Contributes to Vessel Stiffening and Brain
Hypoperfusion
Hypertension is themost validatedmidlife VRF for AD (Duron and
Hanon, 2008; Faraco and Iadecola, 2013; Mayeux and Stern,576 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.2012). Many longitudinal studies observe a positive relationship
between high blood pressure at midlife and increased risk for AD
15–20 years later (Duron and Hanon, 2008). Individuals with
hypertension also have increased senile plaque and NFT loads
compared to normotensive controls (Sparks et al., 1995). How-
ever, results from cross-sectional studies aremore confounding,
as some find increased risk with high blood pressure (BP)
(Cacciatore et al., 1997; Starr et al., 1993), while others find no
association (Morris et al., 2001; Ninomiya et al., 2011). As one
of the documented effects of chronic hypertension is arterial
stiffening, measurement of ankle BP or the ankle-brachial index
(ABI) is thought to be a better predictor of cognitive decline than
systolic BP (Hietanen et al., 2010, 2011; Ix et al., 2010; Tarumi
et al., 2011). The Honolulu-Asia Aging Study found that low
ABI significantly increased the risk of dementia and vascular de-
mentia with hazard ratios (HRs) of 1.66 and 2.5, respectively.
Low ABI may be particularly detrimental for carriers of the detri-
mental APOE4 allele, with a HR of 1.43 (Laurin et al., 2007). A
recent prospective 18-year follow-up study found a significant
association between elevated ankle BP and clinical dementia
at follow up even in individuals with normal brachial BP (HR
1.58) (Hietanen et al., 2013). Elevated pulse wave velocity, which
is another measure of arterial stiffness, was reported to increase
the risk of cognitive decline in the Maine-Syracuse Longitudinal
Study (Elias et al., 2009), Baltimore Longitudinal Study of Aging
(Waldstein et al., 2008), and a third independent study (Hanon
et al., 2005), but not in the Rotterdam Study (Poels et al., 2007).
Chronic hypertension impairs cerebral autoregulation, which
ensures that CBF remains relatively constant (within 80%–
120% of baseline) despite changes to systemic BP (van Beek
et al., 2008). In patients with chronic hypertension, the body
compensates by increasing the threshold for mean arterial pres-
sure at which CBF is maintained. The danger is that the brain
then becomes more vulnerable to hypoperfusion if blood pres-
sure drops (Zazulia, 2009). Supporting this concept, a recent
study comparing cognitively healthy adults who were either
normotensive or hypertensive found that longitudinal decreases
in blood pressure were associated with increased CSF tau phos-
phorylation and memory decline only in the hypertensive cohort
(Glodzik et al., 2014). These changes to cerebral autoregulation
may explain why some studies have found that low BP can
also increase dementia risk (Morris et al., 2000).
Endothelial Function Is Compromised in Type 2Diabetes
Mellitus and Cardiovascular Disease
Next to hypertension, T2DM and various forms of CVD are the
most robust midlife risk factors for AD (Duron and Hanon,
2008). Data from cross-sectional and longitudinal epidemiolog-
ical studies indicate that T2DM increases the relative risk of
AD by 1.4- to 4.4-fold, with inheritance of the APOE4 allele
further worsening disease odds (Vagelatos and Eslick, 2013).
There is a moderate association (odds ratio [OR] 1.3–2.2) of
midlife atherosclerosis and coronary artery disease (CAD) with
increased risk of AD (Hofman et al., 1997; Kalmijn et al., 2000;
Mielke et al., 2007; Newman et al., 2005; van Oijen et al.,
2007), with AD incidence increasing with the severity of CVD
(Hofman et al., 1997; van Oijen et al., 2007).
Although many mechanisms may explain their contribution to
AD, the significant impact that T2DM and CVD have on the
vascular system cannot be ignored. It is well established that
Figure 1. Generation and Maturation of
CNS and Peripheral HDL Species
Left: in the brain, apoE secreted by astrocytes is
lipidated by ABCA1 to form discoidal particles
ranging from 9–17 nm in diameter. ApoE-contain-
ing lipoprotein particles can be taken up by either
LDLR or LRP1 to supply cholesterol to the cell, and
the majority of the endocytosed apoE is recycled.
These apoE lipoprotein particles are present in
interstitial fluid andCSF.CSFapoE lipoproteins are
mature spherical particles that contain a choles-
terol ester core generated through LCAT activity.
Right: in the periphery, lipid-poor apoA-I is syn-
thesized by hepatocytes and enterocytes where it
is lipidated by ABCA1 to form discoidal pre-b-HDL
particles. Further lipids are added by the choles-
terol transporters ABCG1 and SR-B1, and LCAT
activity generates the cholesterol ester core found
in spherical particles. A number of enzymes, such
as PLTP and CETP, remodel these HDL particles,
generating a mix of size and density particles.
ApoA-I containing HDL gains access to the CSF by
a currently unknown mechanism.
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T2DM and CVD, with imbalanced production and secretion of
vasodilators and vasoconstrictors that lead to poor vascular
tone and vessel stiffening. Endothelial expression of adhesion
molecules is also increased, which enhances the transmigration
of inflammatory cells into the vessel wall (Eringa et al., 2013; Van-
houtte et al., 2009). In the case of atherosclerosis, vessel walls
stiffen with the formation and subsequent calcification of
atheroma, which alters blood flow and pressure. Given the
importance of endothelial cell health and blood flow to the brain,
it will be important in future studies to determine whether T2DM
and CVD have similar effects on cerebrovascular endothelial
cells and the neurovascular unit.
In addition to endothelial dysfunction, the plasma lipid profile
of T2DM (Taskinen, 2003) and CVD (Di Angelantonio et al.,
2009) patients is altered compared to that of healthy controls.
Typically, the levels of apoA-I and HDL cholesterol (HDL-C) are
decreased, whereas total cholesterol and LDL cholesterol
(LDL-C) are increased. Importantly, in addition to the well-estab-
lished protective effects of HDL and apoA-I on CVD risk (Mineo
and Shaul, 2012), increased HDL-C and apoA-I levels are also
associated with decreased AD risk (Bonarek et al., 2000; Reitz
et al., 2010; Zuliani et al., 2010), while hypercholesteremia is
associated with an increased risk of AD (Kivipelto et al., 2001,
2002, 2005; Kuo et al., 1998; Lesser et al., 2001; Lesser et al.,
2009; Notkola et al., 1998; Solomon et al., 2009).
Impact of Plasma HDL on Vascular Health and Its
Potential Contribution to AD
Although HDL is best known for its pivotal role in reverse choles-
terol transport (RCT), which is the process by which excess
cholesterol is removed from cells and transported to the liver
for excretion from the body (Mineo and Shaul, 2012), several
lines of evidence suggest that HDL and apoA-I also possess
several potent vasoprotective properties. These include im-
proving vascular function, inhibiting inflammation, suppressing
endothelial cell apoptosis and platelet aggregation, preventing
lipid oxidation, as well as stimulating endothelial repair (Riwanto
and Landmesser, 2013). Although the vast majority of these
studies focus their investigations on larger peripheral blood ves-sels, here we discuss the importance of exploring the potential of
HDL’s influence on cerebrovascular health in future studies.
High-Density Lipoprotein Biology
ApoA-I, the major protein on HDL, is synthesized and secreted
exclusively from the liver and intestine. Newly secreted apoA-I
is lipidated by the ATP-binding cassette transporter A1
(ABCA1), which effluxes phospholipids and cholesterol onto
apoA-I to produce a small and lipid-poor discoidal-shaped
lipoprotein particle (Brunham et al., 2006). Overall, hepatocytes
generate approximately 70% of the total HDL found in plasma,
whereas enterocytes generate the remaining 30%. HDL be-
comes increasingly lipidated in extrahepatic tissues, and leci-
thin-cholesterol acyltransferase (LCAT) activity converts HDL
into spherical lipoprotein particles with a cholesteryl ester
core, which is the predominant form of HDL that circulates
in plasma. Further maturation of HDL particles occurs in
plasma via exchange of lipids and proteins with triglyceride-
rich remnant lipoprotein particles (Masson et al., 2009)
(Figure 1).
Plasma HDL is an extremely heterogeneous class of lipo-
proteins. Several classification schemes have been developed
to identify distinct HDL subclasses, often by shape, buoyant
density, size, or lipid and protein content (Camont et al., 2011)
(Table 1). Recent studies revealed that HDL is composed, in
addition to apoA-I, cholesterol, and phospholipids, of over 200
individual lipid species and over 80 different proteins in normoli-
pidemic plasma (Kontush et al., 2013; Shah et al., 2013). Interest-
ingly, only one-third of the identified protein species have known
roles in lipid metabolism, whereas the remaining proteins are
involved in protease inhibition, regulation of the complement
cascade, and the acute-phase inflammatory response (Hei-
necke, 2009). These observations suggest the intriguing possi-
bility that although HDL is studied most often for its role in
removing excess cholesterol from the body, its ancestral role
may have beenmore aligned with activities of the innate immune
system. How these different constituents of HDL in both healthy
and diseased states may affect cerebrovascular function is now
critically important to address, and the following sections high-
light how HDL dysfunction may contribute to AD pathogenesis
via the cerebrovasculature.Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc. 577
Table 1. Identification of HDL in the Plasma and CNS
HDL Subtype
Plasma CNS
Pre-b-HDL HDL3 HDL2 Astrocyte-Lp CSF-Lp
Density (g/ml) 1.186–1.21 1.125–1.186 1.063–1.125 1.00–1.12 1.063–1.21
Size (nm) <8 8–10 10.3–10.6 9–17 11–20
Shape discoidal spherical spherical discoidal mainly spherical
Major Apolipoproteins apoA-I apoA-I apoA-I apoE, apoJ apoE, apoA-I
Minor Apolipoproteins apoA-II, apoA-IV, apoA-V, apoC-I, apoC-II, apoC-III,
apoC-IV, apoD, apoE, apoF, apoH, apoJ, apoL-1, apoM
– apoA-II, apoA-IV, apoD,
apoC-I, apoC-III, apoJ
HDL species are characterized by size, density, shape, and apolipoprotein content. Lp, lipoprotein.
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In peripheral vessels, plasma HDL regulates vascular tone by
stimulating endothelial nitric oxide synthase (eNOS) activity,
which increases the production of NO to relax the vessel. There
are several mechanisms by which HDL stimulates NO produc-
tion in endothelial cells. First, vasorelaxation requires HDL to
interact with the endothelial scavenger receptor BI (SR-BI); lipid
free apoA-I is insufficient for eNOS activation (Yuhanna et al.,
2001). Second, HDL-associated lysophospholipids activate
eNOS-dependent NO production when bound to the sphingo-
sine-1 phosphate receptor 3 (S1P3) receptor (Nofer et al.,
2004). Third, efflux of cholesterol to HDL by ABCG1 releases
the inhibitory interaction of eNOS with caveolin-1 in endothelial
cells, thereby inducing NO production (Terasaka et al., 2008,
2010). Finally, paraoxonase 1 (PON1) is an HDL-associated pro-
tein implicated in endothelial NO production (Besler et al., 2011).
In addition to glial synthesis, apoE is also produced in the liver
and is a component of several lipoprotein species in plasma,
including HDL. Plasma apoE, which is derived from the liver
and does not intermingle with brain-derived apoE, can be found
within atherosclerotic plaques in the peripheral vasculature
and can also induce endothelial NO production in cultured
peripheral endothelial cells (Stannard et al., 2001). For example,
stimulation of EA.hy926 endothelial cells with conditioned media
from CHO cells transfected with human apoE2, apoE3, or apoE4
showed robust NO production with apoE3, less with apoE2,
and none with apoE4 (Sacre et al., 2003). Additionally, apoE
activates NO production in human umbilical vein endothelial
cells (HUVECs) by suppressing the inhibitory caveolin-1/eNOS
interaction (Yue et al., 2012).
Importantly, the capacity of plasma HDL to induce endothelial
NO production is highly heterogeneous and compromised
in chronic diseases, including coronary artery disease (CAD),
chronic kidney disease, and T2DM (Besler et al., 2011; Gomara-
schi et al., 2013; Sorrentino et al., 2010; Speer et al., 2013).
Although the mechanisms by which these diseases inhibit this
function of HDL remain elusive, an increase of HDL-associated
myeloperoxidase content and activity in diabetic patients and
a decrease in PON1 and sphingosine-1-phosphate (S1P) in
CAD patients have been suggested to reduce HDL function
(Besler et al., 2011; Gomaraschi et al., 2013; Sorrentino et al.,
2010; Speer et al., 2013). In chronic kidney disease patients,
HDL has increased symmetric dimethylarginine (SDMA) content
compared to HDL from healthy controls, which shifts HDL from
scavenger receptor BI (SR-BI) to Toll-like receptor 2 (TLR2)
signaling, consequently reducing NO production and increasing578 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.hypertension (Speer et al., 2013). Importantly, the relationship of
HDL composition and cerebrovascular endothelial NO produc-
tion remains to be determined.
HDL and Inflammation
Both HDL and apoA-I have potent anti-inflammatory activity on
endothelial cells both in vitro and in vivo, including inhibiting in-
flammatory cytokine expression and suppressing the expression
of adhesionmolecules such as VCAM-1 and ICAM-1, which sub-
sequently lowers monocyte adhesion (Calabresi et al., 1997;
Cockerill et al., 1995; Dimayuga et al., 1999; Navab et al.,
1991; Shaw et al., 2008). ApoE also modulates the vascular in-
flammatory response by inhibiting VCAM-1 expression (Stan-
nard et al., 2001). In vitro experiments suggest that reduced
apoA-I levels or apoA-I modifications such as glycation, myelo-
peroxidase-mediated oxidation, and increased serum amyloid
A (SAA) content may inhibit the anti-inflammatory properties of
HDL (Hedrick et al., 2000; Nobe´court et al., 2010; Undurti et al.,
2009; Van Lenten et al., 1995; Zheng et al., 2004). An important
future endeavor will be to determine the degree to which these
functions are retrained within the cerebrovasculature.
HDL, Endothelial Repair, and BBB Integrity
Microvascular disease is a distinct and underappreciated
pathology associated with AD. In the periphery, HDL promotes
repair of damaged endothelial cells and inhibits endothelial cell
apoptosis, properties that are dependent on apoA-I (Riwanto
and Landmesser, 2013). Additionally, HDL is the major plasma
transporter of S1P, which enhances endothelial integrity and
barrier function (Sattler and Levkau, 2009). In the peripheral
vasculature, reduced apoJ and increased apoC-III levels in
HDL of CAD patients impairs the antiapoptotic functions of
HDL on endothelial cells and may shift HDL from an anti- to a
proinflammatory particle (Riwanto et al., 2013). Endothelial repair
after carotid injury in mice is also reduced after injection of HDL
from CAD and chronic kidney disease patients (Besler et al.,
2011; Speer et al., 2013). Finally, in vitro, HDL from diabetic
patients reduces the endothelial proliferative effects of HDL in
an SR-BI-dependent manner (Pan et al., 2012). Key unanswered
questions are whether circulating plasma HDL from healthy sub-
jects can promote repair of cerebrovascular endothelial damage
and whether this function is compromised in patients with CAD
or T2DM.
HDL and Oxidation
HDL and apoA-I are well known to reduce lipid oxidation in
the vasculature and inhibit endothelial thrombotic activation
(Riwanto and Landmesser, 2013). ApoE also possesses allele-
dependent (E2 > E3 > E4) antioxidant activity in vitro (Miyata
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are impaired in patients with acute coronary syndrome and
ischemic cardiomyopathy (Patel et al., 2011, 2013).
Apolipoproteins in Ab Metabolism and Cerebrovascular
Health
ApoE
Inheritance of the APOE4 allele is the most established genetic
risk factor for late-onset AD, decreasing its age of onset and
increasing its severity and progression (Mayeux and Stern,
2012). ApoE, the main lipoprotein in the brain, is synthesized
and secreted by astrocytes and, to a lesser extent, microglia
(Fagan et al., 1999; Pitas et al., 1987). Newly synthesized
apoE-containing lipoprotein particles are lipidated by ABCA1
to form discoidal particles 9–15 nm in diameter (DeMattos
et al., 2001; LaDu et al., 1998) (Figure 1; Table 1). In contrast,
CSF lipoproteins are 11–20 nm spherical particles with a similar
density to the small, dense HDL3 particles found in plasma
(Demeester et al., 2000; Koch et al., 2001; LaDu et al., 1998; Pitas
et al., 1987) (Figure 1; Table 1). In addition to apoE, apoA-I is also
abundant in CSF, with concentrations ranging from 1 to 4 mg/ml
(Demeester et al., 2000; Koch et al., 2001; Roher et al., 2009;
Song et al., 1998). In addition to apoE- and apoA-I-containing
lipoprotein particles in CSF, some authors have also reported a
fraction of particles that contain both apoE and apoA-I (Borghini
et al., 1995; Koch et al., 2001), while others have not (Pitas et al.,
1987). No overt differences in lipoprotein or lipid composition
have been found between different apoE isoforms. Onemajor re-
ported difference is that 20% of apoE forms both homo- and
heterodimers with apoA-II in the CSF of APOE3 carriers, but
not in APOE4 carriers (DeMattos et al., 2001; Demeester et al.,
2000; Guyton et al., 1998; Koch et al., 2001; LaDu et al., 1998;
Montine et al., 1998; Rebeck et al., 1998).
The putative roles of apoE and its isoform-specific effects on
AD pathogenesis have been well studied, though there is still
much to learn (Holtzman et al., 2012). ApoE has well-docu-
mented roles in Abmetabolism, including transport of Ab across
the BBB and in maintaining BBB integrity (Zlokovic, 2013).
ApoE4 is dysfunctional in both of these domains, as apoE4 slows
Ab clearance (Castellano et al., 2011; Deane et al., 2008; Hawkes
et al., 2012; Verghese et al., 2013) and promotes BBB injury in
mice (Hafezi-Moghadam et al., 2007; Methia et al., 2001; Nishit-
suji et al., 2011) (Figure 2). The presence of apoE4 therefore leads
to earlier and more extensive amyloid deposition that can be
detected in living subjects using Pittsburgh Compound B (PIB)
or fluorbetapir PET imaging (Drzezga et al., 2009; Fleisher
et al., 2013; Jagust et al., 2010; Morris et al., 2010; Rowe et al.,
2010), although the resolution of current techniques does not
allow a clear distinction between parenchymal and vascular
amyloid burden (Bacskai et al., 2007; Ikonomovic et al., 2008;
Johnson et al., 2007; Lockhart et al., 2007). Some studies sug-
gest that the risk and severity of CAA is also increased in
APOE4 carriers (Chalmers et al., 2003; Premkumar et al.,
1996), although other studies find that the APOE2 allele can be
overrepresented in patients with CAA (Olichney et al., 2000;
Tian et al., 2004). In a recent study, although CAA load and brain
regions impacted by CAAwere highest in APOE4/APOE4 brains,
CAA was also increased in APOE2/APOE3 subjects compared
to APOE3/APOE3 subjects, indicating that both APOE4 andAPOE2 alleles may impart risk (Nelson et al., 2013). One hypoth-
esis to account for these observations is that apoE4 enhances
Ab deposition within the cerebrovascular walls, while apoE2 in-
creases the risk for hemorrhage of amyloid-laden cerebral blood
vessels (McCarron and Nicoll, 2000). Animal model studies show
that CAA is increased in apoE4-expressing transgenic ADmouse
models (Fryer et al., 2005). Mechanistically, apoE4 retards Ab
clearance across the BBB and via the perivascular drainage
pathway (Castellano et al., 2011; Deane et al., 2008; Hawkes
et al., 2012; Verghese et al., 2013), potentially driving CAA forma-
tion and BBB breakdown. Binding of Ab to apoE4 also shifts
BBB-mediated clearance primarily from LRP1 to VLDLR (Deane
et al., 2008), which has a much slower rate of internalization (Li
et al., 2001).
In contrast to the detrimental effect of apoE4 on Ab clearance,
both transgenic and gene therapy approaches show that apoE2
promotes Ab removal and decreases plaque burden (Castellano
et al., 2011; Dodart et al., 2005; Hudry et al., 2013). A recently
study by Hudry et al. (2013) showed that intraventricular injection
of adeno-associated virus constructs expressing human apoE
isoforms resulted in stable transduction of the choroid plexus
and ependymal cells that led to widespread distribution of trans-
duced apoE, including its presence in ISF. Importantly, even
modest expression, namely 10% of endogenous murine apoE,
significantly accelerated Ab clearance with apoE2 > apoE3 >
apoE4 in symptomatic animals. The observed changes in Ab
metabolism correspondedwith preservation of synaptic integrity
in the vicinity of plaques, and no overt neurotoxicity or BBB dam-
age was observed (Hudry et al., 2013). Taken together, these
studies provide considerable support for the feasibility of
apoE2-directed therapies for AD.
Lipidation of apoE by the cholesterol and phospholipid
transporter ABCA1 is a critical determinant of apoE function
in Ab clearance (Donkin et al., 2010). Specifically, increasing
the amount of lipids carried on apoE by either genetic or pharma-
cological manipulations of ABCA1 levels improves Ab clearance,
whereas inhibiting apoE lipidation impairs Ab clearance (Hirsch-
Reinshagen et al., 2005; Koldamova et al., 2005; Wahrle et al.,
2008). However, it is essential to note that ABCA1 also catalyzes
the lipidation of apoA-I produced in the periphery, which is the
rate-limiting step in plasma HDL biogenesis (Lund-Katz and Phil-
lips, 2010). Therefore, deleting total ABCA1 activity using genetic
methods or increasing ABCA1 activity using systemic adminis-
tration of small molecules that induce ABCA1 expression will
therefore affect both apoA-I levels and function in plasma and
apoE levels and function in the brain, and the relative contribu-
tions of these two pools of lipoproteins on neuropathological
and behavioral outcomes is not clear (Stukas et al., 2012).
Although overexpression of ABCA1 specifically in the brain is
sufficient to reduce parenchymal amyloid burden in PDAPP
mice (Wahrle et al., 2008), it is not yet known whether enhance-
ment of both apoE and apoA-I functions may be even more
beneficial, particularly with respect to cerebrovascular dysfunc-
tion in AD.
Another potential player in the lipidation of apoE is ABCA7.
ABCA7 is highly expressed in the brain and, when overex-
pressed in human embryonic kidney (HEK) cells, can mediate
the transfer of phospholipids, and to a lesser extent cholesterol,
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Figure 2. Influences of Lipoproteins in Alzheimer’s Disease Development
Top: under normal circumstances, apoE- and apoA-I-containing lipoproteins have direct protective effects on the vasculature. In the CNS compartment, apoE
promotes BBB integrity by inhibiting MMP activation in pericytes as well as facilitating clearance of Ab from the CNS to the blood via LRP1. From the luminal side
of the vessel, HDL particles in bloodwork to protect endothelial cell health and repair by signaling in anti-inflammatory and antiapoptotic pathways and promoting
NO secretion to cause vasorelaxation. In addition, apoA-I lipoproteins are present within the CSF and positively influence the perivascular drainage of Ab in an
unknown manner. Middle left: inheritance of the APOE4 allele is detrimental, as apoE4 appears to exhibit both loss of protective functions and gain of toxic
functions. ApoE4 reduces BBB integrity by activating MMPs in pericytes, leading to degradation of tight and adherens junction proteins within endothelial cells,
thereby disrupting the integrity of the barrier. ApoE4 also slows Ab clearance across the BBB by shifting clearance from LRP1 to VLDLR, which has amuch slower
rate of endocytosis. In addition, there is atrophy of the VSMC layer and thickening of the basement membrane in the CNS vessels of APOE4 carriers, impairing
vessel contraction that negatively impacts CBF and Ab clearance. Middle right: vascular and metabolic diseases, such as CAD and TDM2, impair HDL function
and promote so-called dysfunctional HDL in the blood compartment. The vasoprotective effects are then lost, and in certain conditions HDL becomes proin-
flammatory and proapoptotic. In addition, impairment of NO production reduces VSMC relaxation, leading to potential impairment of Ab perivascular drainage
and subsequent CAA. Bottom: a model of potential synergy between genetic and environmental risk factors on lipoprotein function that exacerbates AD
pathogenesis via dysfunctional apoE lipoproteins in the CNS and dysfunctional HDL in the blood compartment.
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ABCA7 is also implicated in the host defense system, with critical
roles in SREBP-2-regulated phagocytic activity in response to
infection or injury (Tanaka et al., 2011). Importantly, ABCA7
has been identified as a susceptibility locus for AD (Hollingworth
et al., 2011; Karch et al., 2012; Reitz et al., 2013; Vasquez et al.,
2013). In African Americans, the effect size of the ABCA7
rs115550680 SNP is comparable to that of apoE4 (Reitz et al.,
2013). In transgenic AD mice, deletion of ABCA7 leads to
increased Ab and amyloid deposits (Kim et al., 2013b), but
effects on cognitive function are reportedly mild (Logge et al.,
2012). Further research will be required to delineate the potential580 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.mechanisms by which ABCA7 influences AD risk and whether its
effects are exerted via apoE.
ApoE4 also affects cerebrovascular health independently of its
role in Ab metabolism (Zlokovic, 2013) (Figure 2). In cognitively
normal APOE4 adults, decreased CBF and altered fMRI connec-
tivity are evident prior to amyloid development or decreasedCSF
Ab42 levels (Bookheimer et al., 2000; Dennis et al., 2010; Filippini
et al., 2009, 2011; Lind et al., 2006; Sheline et al., 2010;Wierenga
et al., 2013; Wishart et al., 2006). ApoE4 is also associated with
reduced glucose metabolism in cognitively normal older people,
again independent of amyloid deposition (Jagust et al., 2012).
Postmortem analyses of AD patients show that BBB breakdown
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apoE4 is less able than apoE3 to maintain BBB integrity through
LRP1-mediated signaling to pericytes, which suppresses inflam-
mation (Bell et al., 2012). Reduced CBF, vascular abnormalities,
BBB damage, and leakage of serum proteins into the extravas-
cular space are observed in young apoE4 and apoE/ mice.
These cerebrovascular changes were attributed to the activation
of MMPs in pericytes. Importantly, these vascular defects pre-
cede neuronal dysfunction (Bell et al., 2012). Lastly, aged
apoE4 mice develop thickening of the basement membranes
even in the absence of detectable loss in capillary density
(Hawkes et al., 2012).
ApoA-I
Although apoA-I is not produced by glia or neurons, it is present
in the CSF at relatively high levels of 0.07–4 mg/ml or 0.1%–0.5%
of plasma levels (Chiba et al., 1997; Demeester et al., 2000;
Fukuyama et al., 2000; Koch et al., 2001; Pitas et al., 1987; Roher
et al., 2009; Saito et al., 1997; Song et al., 1997, 1998). ApoA-I in
the CNS has been hypothesized to originate from direct trans-
port of apoA-I from plasma across the blood-brain and/or
blood-CSF barrier by an unknown mechanism (Figure 1). While
the transport of apoA-I in peripheral aortic endothelial cells is
dependent on ABCA1 and the ectopic beta adenosine triphos-
phatase (ATPase) (Cavelier et al., 2006, 2012), whether apoA-I
transports across the BBB is not clear. Human serum albumin
nanoparticles covalently modified with apoA-I injected into the
tail vein of rats or mice could be detected within brain capillary
endothelial cells (BCECs) and brain tissue parenchyma 30 min
after injection by electron microscopy (Zensi et al., 2010).
In vitro, transcytosis of protamine-oligonucleotide nanoparticles
across confluent monolayers of porcine BCECs was increased
by coating with apoA-I, an effect that was abolished by blocking
SR-BI (Kratzer et al., 2007). Recently, BBB transport of plasmids
encoding interferon alpha (IFNa) alone or fused to apoA-I was
measured by examining the concentration of IFNa and its target
genes in the brain following hydrodynamic infusion in mice.
Fusion of IFNa to apoA-I changed its mode of transport into
the brain from diffusion to a saturable mechanism independent
of SR-BI (Fioravanti et al., 2012). Clearly, more research is
needed to determine the mechanisms by which apoA-I enters
the CNS.
Despite the clear presence of apoA-I in CSF, the role of apoA-I
in AD pathogenesis remains controversial. Several studies have
observed reduced circulating levels of HDL and apoA-I in AD
patients compared to age-matched healthy controls (Kawano
et al., 1995; Kuriyama et al., 1994; Merched et al., 2000), and
decreased apoA-I levels have also been reported in brain tissue
and CSF of probable (Puchades et al., 2003) and neuropatholog-
ically confirmed AD patients (Castan˜o et al., 2006; Roher et al.,
2009). However, two other studies found no changes in frontal
lobe or CSF levels of apoA-I in AD patients, regardless of
APOE genotype (Harr et al., 1996; Song et al., 1997). More
studies are required to determine if CNS apoA-I levels are altered
in AD patients and whether this may be affected by APOE
genotype.
Despite the unclear association between CNS apoA-I levels
and AD pathophysiology, insights into an intriguing association
between apoA-I and CAA have been generated in preclinical
experiments, where genetic manipulation of apoA-I levels wasfound to selectively affect CAA pathology, inflammation, and
cognition in APP/PS1 mice (Lefterov et al., 2010; Lewis et al.,
2010). Intriguingly, transgenic overexpression of human apoA-I
from its endogenous promoter in liver and intestine selectively
reduced cerebrovascular amyloid by 44% in APP/PS1 mice
without affecting total or parenchymal Ab loads or Ab production
(Lewis et al., 2010). APP/PS1 hApoA-I Tg mice also exhibited a
marked decrease in the number of activated astrocytes, with a
trend toward decreased microglial activation. Conversely, defi-
ciency of apoA-I led to increased levels of vessel-extracted
Ab40 and Ab42 by 10-fold and 1.5-fold, respectively, in APP/
PS1 apoA-I/ mice compared to littermate APP/PS1 controls
(Lefterov et al., 2010). Although no behavioral deficits were
observed in aged apoA-I/ mice, deletion of apoA-I from
APP/PS1 mice exacerbated their spatial learning and memory
retention as analyzed by Morris water maze (MWM) (Lefterov
et al., 2010). In contrast, overexpression of hApoA-I prevented
cognitive decline of APP/PS1 mice (Lewis et al., 2010). These
studies demonstrate that apoA-I derived originally from hepato-
cytes or enterocytes can affect cognitive function and cerebro-
vascular amyloid burden in vivo.
In vitro, both lipid-free and lipidated apoA-I bind Ab40 and
Ab42, inhibit its aggregation into fibrils, and reduce Ab-induced
cytotoxicity, oxidative stress, and neuronal degeneration in cell
culture (Koldamova et al., 2001; Lefterov et al., 2010; Paula-
Lima et al., 2009). In BV2 microglial cells, apoA-I can enhance
cellular degradation of Ab42. Although binding to apoJ has
been shown to expedite clearance of Ab40 across the blood-
brain barrier (Bell et al., 2007), whether apoA-I has any effect
on brain-blood or blood-brain transport or perivascular drainage
of Ab has not be determined. Given the known pleiotropic bene-
ficial effects of apoA-I on peripheral endothelial cells, there is a
considerable potential for apoA-I to provide similar support to
the endothelial cells of the CNS.
Enhancing Lipoprotein Function as a Preventative or
Therapeutic Approach for AD
Despite decades of intense activity, discovery of an effective
disease-modifying therapeutic for AD has consistently failed,
particularly for APOE4 carriers. Although there is a growing
consensus that VRF comorbidities contribute to AD pathology
and cognitive decline, clinical trials with statins (McGuinness
and Passmore, 2010; Shepardson et al., 2011b), antihyper-
tensive (Peters and Beckett, 2009), and anti-inflammatory
agents (Alzheimer’s Disease Anti-inflammatory Prevention Trial
Research Group, 2013) in symptomatic AD patients have not
proven successful, possibly because these treatmentswere initi-
ated beyond the therapeutic window for efficacy. However, the
protective effect of HDL for CVD has been well established for
decades, andmajor efforts are underway to develop HDL-based
therapies with atherosclerosis being the primary indication for
many current studies. Infusion of HDL- or apoA-I-based formula-
tions, and small molecules designed to increase HDL and apoA-I
levels, are the two major approaches that have reached clinical
development with respect to HDL therapeutics. Of critical impor-
tance is the increased recognition that assays of specific HDL
subfractions or HDL functional properties, rather than the static
measures of HDL-C levels that are currently used in the clinic,
are likely to be required for success in CVD indications. GivenCell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc. 581
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development for CVD, and improving either apoE or apoA-I func-
tion provides neuropathological and cognitive benefits in preclin-
ical AD studies, targeting the cerebrovasculature via HDL could
be a potentially desirable approach for AD.
Liver X Receptor and Retinoid X Receptor Agonists
Increase CNS ApoE Levels and Function
Liver X receptors (LXRs) are nuclear transcription factors that
dimerize with retinoid X receptor (RXR) and regulate expression
of target genes involved in cholesterol metabolism, inflamma-
tion, and glucose metabolism. LXR agonists are best known
for their ability to induce RCT by stimulating the expression of
ABCA1, ABCG1, and apoE (Im and Osborne, 2011). Multiple
groups have consistently shown that administration of synthetic
LXR agonists, T0901317 and GW3965, improves cognitive per-
formance with or without reductions in Ab deposition or amyloid
burden (Donkin et al., 2010; Jiang et al., 2008; Koldamova et al.,
2005; Riddell et al., 2007; Vanmierlo et al., 2011; Wesson et al.,
2011). Interestingly, although not a direct LXR target, CNS
apoA-I protein levels were markedly increased in symptomatic
APP/PS1 mice treated with GW3965 compared to control ani-
mals independent of ABCA1 (Stukas et al., 2012). As systemic
exposure to LXR agonists will also affect HDL levels and function
in plasma, it will be interesting to determine how much of the
beneficial effect of LXR agonists in AD mice may be due to
changes in peripherally derived apoA-I-based HDL versus
CNS-derived apoE.
Interest in the RXR agonist bexarotene surged when Cramer
et al. demonstrated a rapid clearance of soluble Ab and amyloid
and a reversal of memory, social, and olfactory deficits in APP/
PS1, APPPS1-21, and Tg2576 transgenic AD mouse models
(Cramer et al., 2012). Bexarotene, like LXR agonists, also stimu-
lates expression of ABCA1, ABCG1, and apoE in the CNS
(Cramer et al., 2012; Ulrich et al., 2013). However, questions
arose when four independent laboratories attempted to repeat
the results. While all of the studies observed increased CNS
ABCA1 and apoE levels, only two observed decreases in soluble
Ab (Fitz et al., 2013; Veeraraghavalu et al., 2013), and none
observed any change in amyloid plaque burden or number
(Fitz et al., 2013; Price et al., 2013; Tesseur et al., 2013; Veerar-
aghavalu et al., 2013). Both Fitz et al. and Tesseur et al. noted
cognitive benefits even in the absence of changes to amyloid
burden, but the authors noted that interpretation of their results
was confounded due to the negative side effects of bexarotene
(Fitz et al., 2013; Tesseur et al., 2013). The discrepancies among
these studies could be because plaque burden is poorly corre-
lated with cognition and memory (Landreth et al., 2013), which
has also been observed in humans (Johnson et al., 2012). The
most recent study using bexarotene failed to reduce plaque
burden or provide any cognitive benefit to APP/PS1 mice
(LaClair et al., 2013).
Despite several preclinical studies that show some benefit
with synthetic LXR and RXR agonists, further development of
these compounds for human use is greatly challenged by several
negative side effects. LXR agonists, particularly compounds
that target LXRa, potently induce transcription of fatty acid syn-
thase (FAS) and SREBP1-c, leading to hypertriglyceremia and
hepatic steatosis (Grefhorst et al., 2002; Repa et al., 2000; Ulrich
et al., 2013). In addition to these undesirable metabolic effects,582 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.patients treated with the LXR agonist LXR-623 developed
CNS-related adverse effects, including delirium in the highest
two doses evaluated in a single ascending dose study in healthy
subjects (Katz et al., 2009). Although bexarotene is currently
approved for use in lymphoma and is entering phase I clinical
trials for AD, patients treated with bexarotene can develop com-
bined dyslipidemia with increased triglyceride and VLDL-C and
reduced HDL-C levels, changes that are caused by increased
cholesterol ester transfer protein (CETP) activity (de Vries-van
der Weij et al., 2009), and also can rapidly develop hypothyroid-
ism (Torino et al., 2013). Given that LXR agonists can be effica-
cious in reversing arthrosclerosis, diabetes, and AD pathology
in mice, interest in developing more specific or selective LXR
agonists still continues (Loren et al., 2013). However, as clinical
proof of concept still remains elusive for safe LXR agonists,
methods to improve HDL function independent of LXR/RXR
modulators are highly desirable.
HDL and ApoA-I Infusion
Infusion of reconstituted or recombinant HDL particles into the
circulation is a direct approach to increase HDL levels. The first
studies used apoA-I Milano, which is a naturally occurring ge-
netic variant of apoA-I that protects from CVD despite reduced
circulating HDL-C levels (Sirtori et al., 2001). Although apoA-I
Milano infusions promoted regression of atherosclerotic plaques
to a greater extent than apoA-I WT after 5 weeks of treatment, no
further trials have been reported (Nissen et al., 2003). A second
approach uses autologous delipidated apoA-I injected back
into the patient. In a trial of 28 acute coronary syndrome patients
receiving 7 weekly infusions of autologous delipidated apoA-I,
the levels of pre-b-HDL, which is thought to be particularly active
in promoting RCT, increased an average of 28-fold compared to
baseline levels, and a trend toward decreased atheroma volume
was observed (Waksman et al., 2010). A third approach uses
HDL infused as discoidal recombinant particles. For example,
CSL-111, a preparation of human apoA-I purified from plasma
reconstituted with soy phosphotidylcholine, was investigated in
the ERASE Trial in 183 patients with acute coronary syndrome
in 4 weekly infusions of 40 or 80 mg/kg. The high dose arm
was terminated due to elevated hepatic transaminase levels,
and although the lower dose was well tolerated, it failed to
meet the primary endpoint (Tardif et al., 2007). CSL-112 is a re-
formulated version that, immediately after infusion into rabbits,
was found to disproportionately increase the cholesterol efflux
capacity of HDL. The rapid rise in cholesterol efflux capacity
coincides with the remodeling of CSL-112 into low molecular
weight particles that promote ABCA1-mediated cholesterol
efflux (Diditchenko et al., 2013). In healthy subjects, a single infu-
sion of CSL-112 led to an immediate reduction in HDL particle
size, increased cholesterol efflux capacity, and net exit of tissue
cholesterol to HDL (Easton et al., 2013).
Small Molecule HDL Modulators
Many enzymes are involved in the biogenesis and metabolism of
HDL particles and have been the subject of drug discovery
efforts for CVD, albeit none have so far proven successful.
Numerous trials have shown that niacin has no beneficial effects
on CVD risk (Group, 2013). Furthermore, the CETP inhibitors tor-
cetrapib and dalcetrapib failed in clinical trials due to adverse,
presumably off-target effects on blood pressure and lack of effi-
cacy on cardiovascular outcomes, respectively (Barter et al.,
Cell Metabolism
Review2007; Schwartz et al., 2012). However, anacetrapib and evace-
trapib are currently in clinical trials (Wright, 2013). As CETP is
present in human brain and its CNS functions are not well under-
stood, it will be important to evaluate the effect of CETP inhibition
on AD-relevant outcomes.
RVX208: A Small Molecule ApoA-I Modulator
RVX208 is a first in class small molecule that increases endoge-
nous apoA-I production and is currently in development for acute
coronary syndrome, atherosclerosis, and AD (Bailey et al., 2010).
RVS208 was recently evaluated in the Phase 2b ASSURE clinical
trial, which is a 26-week, double-blind, randomized, parallel
group, placebo-controlled trial with 324 subject with low
HDL-C levels. The RVX208-treated group demonstrated
reduced coronary atheroma volume, increased apoA-I levels,
and increased HDL-C levels (Nicholls et al., 2012). Although
this study did notmeet its primary endpoint, a third party analysis
of the ASSURE data showed that patients receiving RVS208 in
combination with rosuvastatin had a highly statistically signifi-
cant plaque reduction of 1.43%, exceeding the prespecified pri-
mary endpoint by more than 2-fold (Resverlogix, 2013).
With respect to AD, an exploratory Phase Ia trial that enrolled
24 subjects for a double-blind, placebo-controlled, dose-escala-
tion study for a period of 7 days was reported by Resverlogix
to lead to a clear but nonsignificant trend toward a 12%–14%
increase in plasma Ab40 levels at 8 mg/kg dose after 7 days
of dosing compared with controls (Resverlogix, 2008). In
the ASSERT Phase II randomized, placebo-controlled, dose-
ranging study of 299 patients with stable coronary artery dis-
ease, 150mg of RVX208 (twice daily) led to a significant increase
in plasma Ab40 levels from baseline and, in the quartile of
patients with the lowest plasma Ab40 levels at baseline, a
13.4% increase in plasma Ab40 levels compared with placebo
(Resverlogix, 2011). These intriguing observations support the
hypothesis that RVX208 can stimulate the release of Ab40 from
the brain, consistent with the effects of genetic upregulation of
apoA-I levels in AD mice. Further evaluations of RVS208 in the
modulation of AD pathogenesis using double-blind placebo-
controlled clinical trials are eagerly awaited.
Exercise
A wealth of epidemiological literature associates high levels of
physical activity with numerous health benefits, including a lower
risk of CVD, hypertension, stroke, and dementia. The Cooper
Center Longitudinal Study (CCLS) recently reported that higher
midlife fitness levels are associated with reduced risk of all-
cause dementia later in life (Defina et al., 2013). Higher fitness
levels at midlife correlate with both reduced dementia incidence
and reduced adjusted risk for dementia independent of cardio-
vascular risk factors, including BMI, hypertension, diabetes,
hyperlipidemia, and smoking. These observations suggest that
the beneficial effect of exercise includes both vascular and
nonvascular mechanisms. The Finnish Alzheimer Disease
Exercise Trial (FINALEX) concluded that intense and long-term
exercise slowed the decline of physical functioning of AD
patients with no net increase in the total cost of health or social
services and with no significant adverse effects (Pitka¨la¨ et al.,
2013). However, a new report from the Rotterdam Study found
only a weak beneficial association between self-reported phys-
ical activity and dementia in a cohort of 4,406 elderly persons
aged 61–97 years and within only 4 years of follow up (de Bruijnet al., 2013). These findings were conserved after further adjust-
ments for cardiovascular risk factors, including smoking, hyper-
tension, BMI, diabetes, total cholesterol, and HDL cholesterol as
well as for incident AD compared to incident dementia.
Of particular interest is a recent study suggesting that exercise
may mitigate the detrimental effects of APOE4 on amyloid depo-
sition (Head et al., 2012). In this study, 201 cognitively normal
adults (clinical dementia rating [CDR] score 0) aged 45–88 years
were assessed for exercise engagement over 10 years. Subjects
were grouped into low- or high-exercise groups and evaluated
with PIB amyloid imaging and CSF Ab measurements. As
expected, APOE4 carriers had higher mean cortical PIB binding
(MCPB) than non-APOE4 carriers, and exercise reduced MCBP
levels in both groups. The remarkable observation, however,
was that MCBP in APOE4 carriers with high exercise exposure
was comparable to that of non-APOE4 carriers, even when sex
and other potential confounding health variables were included
as covariates. Unlike MCBP, however, there was no interaction
between exercise and APOE4 status on CSF Ab42 levels. A
similar association of aerobic fitness with better performance
on several cognitive tasks was reported for community-dwelling
cognitively normal older women (Etnier et al., 2007) and in
middle-aged APOE4 carriers after controlling for age, gender,
and education (Deeny et al., 2008). Together, these studies sug-
gest that high levels of physical activity may be an especially
important lifestyle modification that APOE4 carriers can use to
reduce their risk for dementia.
Exercise improves cardiovascular health through a multitude
of mechanisms, one of which is through its effects on lipoprotein
metabolism. Exercise enhances the ability of HDL to promote
RCT, raises plasma pre-b-HDL levels, increases LCAT, de-
creases CETP, and enhances the attenuation of TLR-4 signaling
in cells of the innate immune system (Blazek et al., 2013).
Because exercise is also often associated with altered dietary
patterns and reduced BMI, it is challenging to delineate the
effects of exercise alone on HDL levels and function. Neverthe-
less, a meta-analysis of 25 randomized controlled clinical trials
evaluating aerobic exercise alone (without diet or drug therapy)
reported that an exercise level of 5.3 METs significantly
increased HDL-C levels by 2.53 mg/dl, with exercise duration
being the most important determinant of the HDL response
(Kodama et al., 2007). Roughly speaking, a level of exercise of
1500–2200 kcal/week is associated with a 3.5–6.0 mg/dl in-
crease in HDL-C and a 7–20 mg/dl decrease in TG levels (Durs-
tine et al., 2001). Potentially more important than HDL-C levels,
however, is how exercise may improve HDL function. For
example, exercise has been reported to increasing the choles-
terol efflux capacity of HDL isolated from metabolic syndrome
patients (Casella-Filho et al., 2011), although this was not
observed in a previous study (Ribeiro et al., 2008). In another
study, exercise training in chronic heart failure (CHF) patients
increased the ability of their HDL to promote NO production
and flow-mediated dilatation (Adams et al., 2013).
Conclusion
The extensive vascular system of the CNS is relied upon not only
for the delivering of nutrients and removal of wastes, but also for
forming a highly specific and selective barrier that regulates
transport into and out of the brain and participates in an arrayCell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc. 583
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able data suggest a potential synergic role of apoE and apoA-I in
brain vascular health and AD pathophysiology. As apoE cannot
cross the BBB (Linton et al., 1991), the pool of apoE in the
CNS is distinct from that in the circulation. Conversely, apoA-I
found in CSF or brain tissue is thought to be derived from the
plasma pool via transport across the BBB or blood-CSF barrier.
Even though the concentration of apoA-I in CSF is an order of
magnitude lower than its concentration in plasma (Koch et al.,
2001), by mass, apoA-I and apoE levels in CSF are similar
(Demeester et al., 2000; Koch et al., 2001; Pitas et al., 1987;
Roher et al., 2009; Song et al., 1998). ApoE and apoA-I may
therefore have complementary roles in protecting vascular
health in the CNS, with glial-derived apoE primarily working
from the abluminal side of the vessel and circulating apoA-I
acting from the luminal side (Figure 2).
Hypertension, hypercholesteremia, obesity, T2DM, and CVD
all have potentially significant consequences for cerebrovascular
health and may be early and, importantly, preventative factors
for AD risk (Mayeux and Stern, 2012). Plasma HDL and its
main protein component apoA-I have several beneficial func-
tions that are well established to maintain vascular endothelial
health in peripheral vessels, including effects on RCT, vascular
tone, inflammation, and endothelial repair (Mineo and Shaul,
2012). Importantly, these functional properties of HDL may be
vastly more informative than the levels of HDL-C per se. The
potential beneficial effects of apoA-I and HDL on cerebrovascu-
lar health, CAA, Ab40 metabolism, and cognitive function
deserve further study, particularly with respect to potential inter-
actions with APOE genotype.
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